(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 131.95% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Abeona Therapeutics's revenue in 2024 is $3,500,000.On average, 1 Wall Street analysts forecast ABEO's revenue for 2024 to be $453,046,044, with the lowest ABEO revenue forecast at $453,046,044, and the highest ABEO revenue forecast at $453,046,044. On average, 3 Wall Street analysts forecast ABEO's revenue for 2025 to be $667,213,265, with the lowest ABEO revenue forecast at $411,860,040, and the highest ABEO revenue forecast at $1,013,175,698.
In 2026, ABEO is forecast to generate $1,995,461,894 in revenue, with the lowest revenue forecast at $1,565,068,152 and the highest revenue forecast at $2,425,855,636.